Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapySolid TumorsProtocol groupEndocrine and Neuroendocrine OncologyGastroenterologic OncologyGynecological OncologyNeuro-OncologyradiotherapyDiseaseBile Duct CarcinomaNeuroendocrine CarcinomaOvarian TumorPancreatic CancerTumor Biomarker DefinedSubgroupBRAF V600-MutationgBRCA mutationKRAS G12C-MutationMismatch Repair - deficient / Microsatellite Instability - high (dMMR/MSI-H)PALB2 mutationICD10C24.-C24.0C24.1C24.8C24.9C25.-C56C80.9MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsCarcinoma, NeuroendocrineCommon Bile Duct NeoplasmsNeoplasmsPancreatic NeoplasmsSequenceGEMC1000, Pancreatic Ca, A (PID285) -|- B (PID286)GEMC1000/CAPE830, Pancreatic Ca (PID1980) -|- CAPE830/Radiation (PID1968)GEMC1000/ERLO100, Pancreatic Ca, A (PID512) -|- B (PID513)mFOLFIRINOX (OXAL85/CFOL400/IRIN135/FU2400), Pancreatic Ca, perioperative (PID2687) -|- mFOLFIRINOX (OXAL85/CFOL400/IRIN135/FU2400), Pancreatic Ca, perioperative (PID2687)NEOLAP - NPAC125/GEMC1000, Pancreatic Ca, neoadj. (PID782) -|- FOLFIRINOX (OXAL85/CFOL400/IRIN180/FU2400) (PID789) -|- (PID810)ChemotherapyChemo-substanceCapecitabineCisplatinDabrafenibErlotinibFluorouracilFolinic acidGemcitabineIrinotecanIrinotecan pegylated liposomalNab-paclitaxelOlaparibOxaliplatinPembrolizumabSotorasibTemozolomideTrametinibChemo-substanceCapecitabineCisplatinDabrafenibErlotinibFluorouracilFolinic acidGemcitabineIrinotecanIrinotecan pegylated liposomalNab-paclitaxelOlaparibOxaliplatinPembrolizumabSotorasibTemozolomideTrametinibChemo-substanceCapecitabineCisplatinDabrafenibErlotinibFluorouracilFolinic acidGemcitabineIrinotecanIrinotecan pegylated liposomalNab-paclitaxelOlaparibOxaliplatinPembrolizumabSotorasibTemozolomideTrametinibChemo-substanceCapecitabineCisplatinDabrafenibErlotinibFluorouracilFolinic acidGemcitabineIrinotecanIrinotecan pegylated liposomalNab-paclitaxelOlaparibOxaliplatinPembrolizumabSotorasibTemozolomideTrametinibNo. Substances1234 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideSupportive substanceBalanced Crystalloid SolutionCotrimoxazoleDexamethasoneFosaprepitantGranisetronHydrocortisoneMagnesiumMagnesium sulfateMinocyclinePegfilgrastimPotassium chlorideNo. Substances123457Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationFirst lineRelapse therapySecond lineTherapy phaseMaintenanceneoadjuvantneoadjuvant / adjuvantTherapy intentioncurativepalliativeRisksAnemia Hb below 8g/dlAnemia Hb below 10g/dlAnorexiaArthalgiaAstheniaCardiotoxicityColitisConstipationDiarrheaEmetogenicityEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Exanthema, AcneiformFatigueFebrile NeutropeniaGastrointestinal ToxicityHand-Foot SyndromeHeadacheHepatotoxicityHyperglycemiaHypertensionHyperthyroidismHypokalemiaHyponatremiaHypophosphatemiaHypothyroidismIncrease Alkaline PhosphataseIncrease AminotransferasesInfectionsLeukopeniaMucositisMyocarditisNauseaNephritisNeuropathyNeutropeniaPainPneumonitisPruritusPyrexiaRashSepsisThrombocytopenia below 50 000/µlThromboembolic EventVomiting only studiesPublicationAuthorBurris HACecchini MConroy, ThierryConroy TGolan THeinemannHurt CKunzmann VLoehrer PMaio M Moore MJNeoptelemos JOettle HO´Reilly ESalama AKSStrickler JStrosberg JRVon Hoff DDWainberg ZAWang-Gillam ADiseaseAdenokarzinom des Pankreas, frühes Stadium, adjuvant, ECOG 0-2forgeschrittenes oder metastasiertes Pankreaskarzinom, Erstlinie, Karnofsky > 70fortgeschrittenes oder metastasiertes Adenokarzinom des Pankreas, gBRCA/PALB2+, Erstlinie, ECOG 0-1Fortgeschrittenes oder metastasiertes Pankreaskarzinom, KRAS p.G12C–mutiert, Zweitlinie, ECOG 0-2Lokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2lokal fortgeschrittenes, nicht-resezierbares Pankreas-Ca, ECOG 0-1met. Pankreaskarzinom, BRCA1 oder BRCA2- Mutation, nach mind. 16 Wochen platinbas. Therapie, ECOG 0-1Metastasiertes Pankreaskarzinom, ECOG 0-1metastasiertes Pankreaskarzinom, Zweitlinie nach Gemcitabin, Karnofsky Status > 50nicht metastasiertes, lokal fortgeschrittenes Adenokarzinom des Pankreas, Erstlinie, ECOG 0-1nicht resezierbares / borderline Adenokarzinom des Pankreas, neoadjuvant, Erstlinie, ECOG 0-2Pankreas-Ca, fortgeschritten oder metastasiert, ECOG 0-2, ErstliniePankreas-Ca, lokal fortgeschritten oder metastasiert, chemo-naivPankreas-Ca, metastasiert, chemo-naiv, Karnofski-Index von 70 und höherPankreas-Ca, nach R0 oder R1-Resektion, Karnofsky Index über 50%, keine vorangegangene Chemo- oder RadiotherapiePankreaskarzinom (Adeno-), metastasiert, ECOG 0-1Pankreaskarzinom, MSI-H/dMMR, Zweitlinie, ECOG 0-1Pankreaskarzinom, Progress unter Erstlinie Gemcitabin, Karnofsky Status >70Pankreaskarzinom, resektabelPankreaskarzinom adjuvant, Adeno-, R0- oder R1-Resektion, Erstlinie, ECOG 0-1pankreatisches neuroendokrines Karzinom, ErstlinieOriginAbteilung für Onkologie und Hämatologie, Charité Berlin, DeutschlandCancer Center, Indiana University, IndianapolisCONKO 003, Universitätsmedizin Berlin Charité, Zentrum für TumormedizinDepartment of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, FloridaDuke University, Durham, NC, NCI-MATCH Trial Subprotocol HEuropean Study Group for Pancreatic Cancer, ESPAC-4 trial German Pancreatic Cancer Working Group (AIO-PAK) and NEOLAP investigatorsGroupe Tumeurs Digestives of Unicancer and the PRODIGE IntergroupInstitute for Drug Development, Cancer Therapy and Research Center, San Antonio, USAMedizinische Klinik und Poliklinik III, Klinikum Grosshadern, MünchenMemorial Sloan Kettering Cancer Center, New York, NYNational Cancer Institute of Canada Clinical Trials Group; NCIC CTG PA.3 StudieOncology Institute, Sheba Medical Center, Tel Aviv University, Israel, POLO trialTranslational Genomics Research Institute, Phoenix, USAUnicancer-GI/Prodige Group und CCTG, Institute de Cancerologie de Lorraine, NancyUniversity of California Los Angeles, Los Angeles, CA, USA, NAPOLI 3University of Siena and Center for Immuno-Oncology, Department of Oncology, University Hospital, Siena, Italy, KEYNOTE-158 studyUniversity of Texas, M.D. Anderson Cancer Center, Houston, USA, CodeBreaK 100 trialWales Cancer Trials Unit, College of Biomedical and Life Sciences, Cardiff University, United Kingdom, Scalop trialWashington University School of Medicine, St Louis, MO, USA, NAPOLI-1Yale University School of Medicine, New Haven, ConnecticutProtocols in Revision 26 protocols foundProtocols under revision.Capecitabine 750 / Temozolomide 200, pancreatic neuroendocrine carcinoma (PID1313 V1.1)Capecitabine 830 / Radiation, Pancreatic Cancer (PID1968 V2.0)Cisplatin 25 / Gemcitabine 600, Pancreatic Cancer (PID476 V1.1)Dabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197 V1.0)FOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 180 / Fluorouracil 2400, Pancreatic Cancer (PID47 V1.4)FOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 180 / Fluorouracil 2400, Pancreatic Cancer, Neoadjuvant (PID789 V1.0)Gemcitabine 1000 / Capecitabine 830, Pancreatic Cancer (PID1980 V1.2)Gemcitabine 1000 / Capecitabine 830, Pancreatic Cancer Adjuvant (PID766 V1.2)Gemcitabine 1000 / Cisplatin 50, Pancreatic Cancer (PID939 V1.1)Gemcitabine 1000 / Erlotinib 100, Pancreatic Cancer, Part A (PID512 V1.0)Gemcitabine 1000 / Erlotinib100, Pancreatic Cancer Part B (PID513 V1.0)Gemcitabine 1000, Pancreatic Cancer, Adjuvant (PID292 V1.1)Gemcitabine 1000, Pancreatic Cancer, Part A (PID285 V1.0)Gemcitabine 1000, Pancreatic Cancer, Part B (PID286 V1.0)Gemcitabine 600 / Radiation, Pancreatic Cancer, Neoadjuvant (PID1161 V1.1)mFOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 135 / Fluorouracil 2400, Pancreatic Cancer, perioperative (PID2687 V1.0)mFOLFIRINOX - Oxaliplatin 85 / Folinic Acid 400 / Irinotecan 150 / Fluorouracil 2400, Pancreatic Cancer, Adjuvant (PID1176 V1.1)Nab-Paclitaxel 125 / Gemcitabine 1000, Pancreatic Cancer, adj. (PID810 V1.0)Nab-Paclitaxel 125 / Gemcitabine 1000, Pancreatic Cancer, neoadjuvant (PID782 V1.0)Nab-Paclitaxel 125 / Gemcitabine 1000, pancreatic cancer (PID287 V1.0)NALIRIFOX - Pegylated Liposomal Irinotecan 50 / Oxaliplatin 60 / Folinic Acid 400 / Fluorouracil 2400, Pancreatic Cancer (PID2475 V1.0)OFF - Oxaliplatin 85 / Folinic Acid 200 / Fluorouracil 2000, Pancreatic Cancer (PID517 V1.1)Olaparib 300, Pancreatic Cancer, Maintenance (PID1475 V1.0)Pegylated Liposomal Irinotecan 70 / Folinic Acid 400 / Fluorouracil 2400, Pancreatic Cancer (PID793 V2.1)Pembrolizumab 200, Pancreatic Cancer (PID2476 V1.0)Sotorasib 960, Pancreatic Cancer (PID2304 V1.0)
